Telix Pharmaceuticals Limited (TLX)
Develops radioactive drugs that find and destroy cancer cells throughout the body.
$10.19+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-21.9%
The outlook
Telix trades at $10.19 and sits roughly midway in its 52-week range. All four analysts covering the stock rate it a Strong Buy, with an average price target about 104% above the current level. The stock shows mixed momentum against its moving averages, though the overall sentiment leans bullish.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 4 analysts
Price trendMixed vs its moving averages
52-week range49% of the way from its 52-week low to high
Price targetAvg target +104% vs current price
Analyst price target
~12-month · 4 analysts$20.78average target+103.9% vs now
Now $10.19
Low $19.43High $21.93
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.45B
52-wk high
$14.27
52-wk low
$6.28
50-day avg
$10.33
200-day avg
$9.30
Trailing P/E
—